AuraLux Laser Debuts, Promising Safer Rejuvenation for All Skin Tones

SMITHFIELD, RI – April 08, 2026 – As the doors open at the American MedSpa Association (AmSpa) annual meeting in Las Vegas this week, the spotlight is on a new device poised to address one of the aesthetic industry's most persistent challenges: providing safe, effective skin rejuvenation for every complexion. Acclaro Medical today announced the showcase of its AuraLux™ 2910 nm Fiber Laser, an advanced system designed not only to deliver high-impact results but also to redefine the standard of care for inclusivity in laser treatments.

Building on the success of its award-winning UltraClear® platform, Acclaro is positioning AuraLux as a comprehensive solution for 'total skin health™'. The company's announcement emphasizes a dual focus: groundbreaking technology coupled with a novel Practice Development Partnership program, signaling a strategic shift from simply selling a device to fostering long-term practice growth.

The Next Generation of Laser Technology

At the heart of AuraLux lies its 2910 nanometer fiber laser. This specific wavelength is significant because it aligns perfectly with the peak absorption of water in the skin. This allows the laser to perform what is known as "cold ablation"—vaporizing tissue with extreme precision while minimizing the transfer of heat to the surrounding area. This is a critical departure from traditional CO2 lasers, which often generate significant thermal damage, leading to longer recovery times and a higher risk of complications.

AuraLux leverages advanced CoolPulse™ technology to deposit ultrafast micro-pulses of energy into targeted skin depths. The result is a treatment that is significantly more comfortable for the patient and requires minimal downtime. While competitors like Sciton offer a similar 2940 nm wavelength with their HALO laser, and companies like Candela and Lumenis utilize Nd:YAG wavelengths and advanced cooling for darker skin, Acclaro's focus on a "cold ablative" fiber laser mechanism is its core differentiator. This technology, inherited and evolved from the UltraClear platform—lauded by NewBeauty Magazine as the "Best Laser Treatment for All Skin Tones"—aims to provide the efficacy of an ablative laser with the safety profile of a much gentler treatment.

Breaking Barriers in Aesthetic Inclusivity

Perhaps the most significant claim attached to AuraLux is its safety and effectiveness for all skin types, including Fitzpatrick skin types IV through VI, which represent individuals with melanin-rich skin. For decades, this demographic has been underserved by the laser rejuvenation market due to a heightened risk of post-inflammatory hyperpigmentation (PIH), hypopigmentation, and scarring. The excess heat from many conventional lasers can inadvertently stimulate melanin production in darker skin, leading to discoloration that can be worse than the original concern.

AuraLux's cold ablative technology directly confronts this issue. By minimizing residual thermal energy, the laser significantly reduces the risk of triggering an inflammatory response and subsequent pigmentation problems. This technological advancement is a game-changer, potentially democratizing access to high-end aesthetic procedures. The underlying technology in Acclaro's platforms has already received FDA clearances and has been the subject of clinical studies and presentations at major dermatological conferences, validating its approach for treating "skin of color" with a reduced risk profile. This makes it possible for practitioners to confidently treat a broader patient base for concerns ranging from fine lines and sunspots to deeper wrinkles and acne scars, regardless of their skin tone.

More Than a Machine: A New Partnership Model for MedSpas

Understanding that a successful aesthetic practice requires more than just advanced equipment, Acclaro is launching AuraLux with a dedicated support ecosystem. The new Practice Development Manager (PDM) program is designed to integrate the device into a clinic's business operations seamlessly. This moves beyond the industry standard of basic clinical training and marketing materials.

"Innovation doesn't stop at the device. From installation to impact, our Practice Development Managers help ensure our customer's investment is transformed into measurable practice growth and superior patient care," said Max Maxwell, VP of Implementation at Acclaro, in the company's press release. The program promises to partner with providers to deliver strategic guidance, clinical insights, and robust business support.

For the medspa owners and managers gathering at AmSpa, this value proposition is compelling. In a competitive market, maximizing return on investment is paramount. The PDM program aims to shorten the learning curve, optimize treatment protocols, and help practices effectively market their new capabilities. By framing the relationship as a partnership, Acclaro is betting that this comprehensive support will be as crucial to a practice's success as the laser's technical specifications.

Versatile Treatments for Every Lifestyle

To maximize its utility, the AuraLux system comes equipped with four distinct treatment modalities designed to be personalized to a patient's specific needs and lifestyle. These options range from quick, no-downtime "prejuvenation" to more intensive renewal treatments.

The 3DMIRACL® is a 10-15 minute treatment targeting the outermost layer of skin to improve brightness, discoloration, and overall texture. For a slightly deeper treatment, REFRESH addresses mild sunspots and fine lines. RENEW targets the dermis to stimulate deep collagen remodeling, addressing more significant wrinkles and scars. Finally, the GLIDE modality uses an advanced in-motion technique, delivering randomized pulses to treat large areas quickly while further reducing the risk of hyperpigmentation.

As practitioners explore the latest innovations on the floor of the Wynn Las Vegas this week, Acclaro's AuraLux will be a focal point. With live demonstrations and expert talks, the company is making its case that the future of aesthetic medicine is not only more effective but also more inclusive and strategically supported. The reception it receives at AmSpa could very well dictate the new benchmark for skin rejuvenation technology.